REPLIGEN CORP Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value
REPLIGEN CORP (RGEN) had Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value of $141.32 per share as of 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue · last filed 2026-07-29
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value $141.32.
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value $143.20.
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value $152.80.
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value $154.31.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value |
|---|---|
| 2026-06-30 | $141.32 10-Q · filed 2026-07-29 |
| 2026-03-31 | $143.20 10-Q · filed 2026-05-06 |
| 2025-12-31 | $152.80 10-Q · filed 2026-07-29 |
| 2025-09-30 | $154.31 10-Q · filed 2025-11-04 |
| 2025-06-30 | $156.29 10-Q · filed 2025-08-07 |
| 2025-03-31 | $160.21 10-Q · filed 2025-04-29 |
| 2024-12-31 | $162.33 10-K · filed 2026-02-26 |
| 2024-09-30 | $164.04 10-Q · filed 2024-11-18 |
| 2024-06-30 | $166.59 10-Q/A · filed 2024-11-18 |
| 2024-03-31 | $166.78 10-Q/A · filed 2024-11-18 |
| 2023-12-31 | $155.59 10-K · filed 2025-03-14 |
| 2023-09-30 | $188.41 10-Q/A · filed 2024-11-18 |
| 2023-06-30 | $157.94 10-Q/A · filed 2024-11-18 |
| 2023-03-31 | $154.72 10-Q/A · filed 2024-11-18 |
| 2022-12-31 | $142.57 10-Q/A · filed 2024-11-18 |
| 2021-12-31 | $115.11 10-K · filed 2023-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |